July 30, 2026

Volition Advances Nu.Q® NETs Platform Towards Commercialization

Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market

HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.



Mr. Gael Forterre, Chief Commercial Officer, Volition commented:

"We are in active discussions with several large diagnostic companies to accelerate the development of Nu.Q® NETs and believe the potential use cases represent a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $3.8 billion."

Professor Djillali Annane, Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) commented:

"This is the first time I have seen so muchdata, so quickly, on a sepsis biomarker with consistent findings. The consistency of data from different teams, across different countries and across different types of sepsis is extremely reassuring.

"Results show that Nu.Q® H3.1 accurately distinguishes sepsis from non-infectious systemic inflammation, is highly correlated with disease severity, and provides excellent prognostic utility for outcomes such as organ failure and mortality[1-4]. Nu.Q® H3.1 provides new and additional information above standard organ failure scores such as APACHE II and SOFA scores[1-4].

"I believe that using the Nu.Q® NETs test to measure elevated H3.1 nucleosome levels as a "**treatable trait**" in sepsis management could be a game changer in modifying a patient's trajectory. Introducing Nu.Q® NETs into hospitals could lead to new ways of treating sepsis, improving patient survival and the quality of life of survivors."

Dr Andrew Retter, Critical Care Lead and Medical Consultant, Volition, said:

"We have amassed a significant body of both scientific and clinical evidence to support the use of Volition's Nu.Q® NETs assay in diseases associated with NETosis. The majority of these papers have now been peer reviewed and published.

"Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test to detect diseases associated with NETosis. Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage and, in severe cases, sepsis, organ failure, and death.

"The findings from this significant body of both scientific and clinical work advance our understanding of nucleosome biology in critical illness and help inform future therapeutic strategies with the ultimate aim of personalizing patient care."

1. Filipini D, et al. (2025). Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failure https://doi.org/10.1186/s13054-025-05415-6
2. Neumann et al, MEDRXIV
3. Haem Rahimi M, et al. (2023) Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock. Ann Intensive Care. doi: 10.1186/s13613-023-01204-y
4. Morimont, L., et al. (2022). NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study. Biomolecules. doi: 10.3390/biom12081038

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements contained or referenced herein, including in any associated video or link, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify such statements.

These forward-looking statements relate to, among other topics, Volition's expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications; and its success in securing, and the terms of, licensing and/or distribution agreements with third parties.

Forward-looking statements are based on current expectations, estimates and projections about Volition's business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition's tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.

Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.

Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-advances-nuq-nets-platform-towards-commercialization-302837879.html

SOURCE VolitionRx Limited